Drug Trial Radar · NCT04844983
A Study to Evaluate Safety, Efficacy of Intralesional Injection of STP705 in Patients With isSCC
Last checked: Nov 19, 2026Latest source record: Mar 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
44
Actual
Start
May 18, 2021
Primary completion
Aug 24, 2022
Study completion Dec 6, 2022
Sponsor
- Lead sponsor
- SirnaomicsIndustry
- Sponsor type
- Industry
- First posted
- Apr 14, 2021
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this trial is to evaluate safety, tolerability and efficacy of various doses of STP705 administered as intralesional injection in subjects with cutaneous squamous cell carcinoma (in situ) skin cancer (isSCC).
Conditions
- Squamous Cell Carcinoma in Situ
Interventions
STP705Drug
The STP705 drug substance is composed of two siRNA oligonucleotides, targeting TGF-β1 and COX-2 mRNA respectively.
Placebo SalineOther
Normal Saline
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with histological clearance of treated isSCC lesionTime frame: 6 weeks
Locations
7 sites in 1 country. Site status is shown where the registry gives one.
Investigate MD
Scottsdale, Arizona
Center for Clinical and Cosmetic Research
Aventura, Florida
Research Institute of the Southeast LLC
West Palm Beach, Florida
Dermatology, Laser and Vein Specialists of the Carolinas
Charlotte, North Carolina
Dermatology Associates of Knoxville
Knoxville, Tennessee
Tennessee Clinical Research
Nashville, Tennessee
Austin Institute for Clinical Research
Pflugerville, Texas
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.